These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32012202)

  • 1. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    Hjorth M; Dandu N; Mellergård J
    PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
    Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    Paolicelli D; Manni A; D'Onghia M; Direnzo V; Iaffaldano P; Zoccolella S; Di Lecce V; Tortorella C; Specchia G; Trojano M
    J Neuroimmunol; 2017 Feb; 303():75-80. PubMed ID: 28043652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
    PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
    Schwichtenberg SC; Wisgalla A; Schroeder-Castagno M; Alvarez-González C; Schlickeiser S; Siebert N; Bellmann-Strobl J; Wernecke KD; Paul F; Dörr J; Infante-Duarte C
    Neurotherapeutics; 2021 Jul; 18(3):1783-1797. PubMed ID: 34244929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
    Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
    Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
    Blumenfeld-Kan S; Staun-Ram E; Miller A
    Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
    Huber JE; Chang Y; Meinl I; Kümpfel T; Meinl E; Baumjohann D
    J Immunol; 2020 Mar; 204(5):1101-1110. PubMed ID: 32034063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.
    Dominguez-Villar M; Raddassi K; Danielsen AC; Guarnaccia J; Hafler DA
    J Autoimmun; 2019 Jan; 96():40-49. PubMed ID: 30122421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Percentage of CD8
    Houston TW; Howlett-Prieto Q; Regenauer C; Testai FD; Yao F; Feng X; Reder AT
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36535763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
    Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
    Front Immunol; 2018; 9():2669. PubMed ID: 30524432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
    Sato DK; Nakashima I; Bar-Or A; Misu T; Suzuki C; Nishiyama S; Kuroda H; Fujihara K; Aoki M
    J Neuroimmunol; 2014 Mar; 268(1-2):95-8. PubMed ID: 24507619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.